This study provides evidence that combining weak antibiotics in one single capsule formulation (rather than multi-individually dissolved drugs) might be the new silver bullet to combat bacteria, and lends further weight to the theory of a bacterial cause for Crohn’s.
Click here to read.
December 2016
“We only need to remember the example of peptic ulcer disease and the original disinclination to accept an infectious underlying mechanism to appreciate that this MAP hypothesis cannot be blindly ignored.”
Click here to read..
May 2016
After enduring the ravages of inflammatory bowel disease, Sydney banker Richard Chesworth has found a path to wellbeing, using the triple antibiotic therapy we call AMAT (anti-MAP antibiotic treatment).
‘Borody has taken much professional flak over his career. When he started doing faecal transplants, some of colleagues suggested he was mentally ill. Transplants are now a mainstream treatment for an intractable form of diarrhoea.
When he developed the triple therapy for H. pylori, there was widespread scepticism too. It’s now standard practice.
“I’m either perceived as innovator or a cowboy but I have been getting more respect in the last few years,” Borody says.’
The London specialist referred to in the article is, of course, Professor Hermon-Taylor.
Click here to read
April 2016
A huge thank-you to team member Annabelle Hall for organising the Mardi Gras Gala and a personal message from Prof John Hermon-Taylor. This was yet another hugely successful Crohn’s MAP Vaccine fund raiser, organised and supported by people who are passionate about curing Crohn’s disease.
Another paper, this time from Australia, which further confirms the connection between MAP and Crohn’s disease.
“A significant association was found between M. paratuberculosis and Crohn’s disease (p = 0.02) that was not related to age, gender, place of birth, smoking or alcohol intake.”
The Association of Mycobacterium avium subsp. paratuberculosis with Inflammatory Bowel Disease
In this new paper, Crohn’s Disease: A Case for MAP Targeted Therapy, Leonie Marloes Vogt makes a compelling case for further investigation into the role of MAP as the cause of Crohn’s disease and highlights how this could lead to new treatment options. We fully agree with you Leonie!
Crohn’s disease (CD) is a severe intestinal inflammatory disease, for which currently no full cure is possible, and of which the pathogenesis is still not fully elucidated. Intestinal bacteria are thought to play a role in the onset, combined with environmental factors, immune factors, and genetic susceptibility of the host. However, we do not fully understand the nature of the disease yet, and as a consequence, this lack in our knowledge may prevent us from developing effective and curative therapies. If we are able to revisit our views on involvement of Mycobacterium avium ssp. paratuberculosis (MAP) a as an important player in this disease, this might open up new options for therapeutic targets.
An exciting new paper published in the last few weeks highlights that many people, even those without clinical signs of disease, are infected with MAP. This adds weight to the argument that MAP is a zoonotic pathogen with a latent state like other mycobacterium such as tuberculosis. MAP is a risk to everyone and there is an urgent need for effective testing and treatment.
Read the full paper here:
On deaf ears, Mycobacterium avium paratuberculosis in pathogenesis Crohn’s and other diseases
